Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).
4087 Background: The management of CCA has evolved as targeted and immune
checkpoint inhibitor (ICPI) therapies have emerged. We used comprehensive genomic …
checkpoint inhibitor (ICPI) therapies have emerged. We used comprehensive genomic …
[HTML][HTML] Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups
One-hundred-fifty-three biliary cancers, including 70 intrahepatic cholangiocarcinomas
(ICC), 57 extrahepatic cholangiocarcinomas (ECC) and 26 gallbladder carcinomas (GBC) …
(ICC), 57 extrahepatic cholangiocarcinomas (ECC) and 26 gallbladder carcinomas (GBC) …
Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations.
JS Ross, K Wang, MM Javle, DVT Catenacci, RT Shroff… - 2015 - ascopubs.org
4009 Background: Intrahepatic cholangiocarcinoma (IHCCA), extrahepatic
cholangiocarcinoma (EHCCA) and gallbladder carcinomas (GBCA) typically present at an …
cholangiocarcinoma (EHCCA) and gallbladder carcinomas (GBCA) typically present at an …
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications
Background Cholangiocarcinoma (CCA) is clinically heterogeneous; intra and extrahepatic
CCA have diverse clinical presentations. Next generation sequencing (NGS) technology …
CCA have diverse clinical presentations. Next generation sequencing (NGS) technology …
Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention
Purpose: Various genetic driver aberrations have been identified among distinct anatomic
and clinical subtypes of intrahepatic and extrahepatic cholangiocarcinoma, and these …
and clinical subtypes of intrahepatic and extrahepatic cholangiocarcinoma, and these …
Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations.
JS Ross, K Wang, DVT Catenacci, J Chmielecki, SM Ali… - 2015 - ascopubs.org
231 Background: Intrahepatic cholangiocarcinoma (IHCCA), extrahepatic
cholangiocarcinoma (EHCCA) and gallbladder carcinomas (GBCA) typically present at an …
cholangiocarcinoma (EHCCA) and gallbladder carcinomas (GBCA) typically present at an …
[HTML][HTML] Practical considerations in screening for genetic alterations in cholangiocarcinoma
TS Bekaii-Saab, J Bridgewater, N Normanno - Annals of Oncology, 2021 - Elsevier
Cholangiocarcinoma (CCA) encompasses diverse epithelial tumors historically associated
with poor outcomes due to an aggressive disease course, late diagnosis, and limited benefit …
with poor outcomes due to an aggressive disease course, late diagnosis, and limited benefit …
Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma.
IM Silverman, K Murugesan, CF Lihou, L Féliz… - 2019 - ascopubs.org
4080 Background: Genomic studies of cholangiocarcinoma (CCA) have identified
actionable alterations in multiple genes including IDH1, IDH2, FGFR2 and BRAF, but no …
actionable alterations in multiple genes including IDH1, IDH2, FGFR2 and BRAF, but no …
Biliary cancer: utility of next‐generation sequencing for clinical management
M Javle, T Bekaii‐Saab, A Jain, Y Wang, RK Kelley… - Cancer, 2016 - Wiley Online Library
BACKGROUND Biliary tract cancers (BTCs) typically present at an advanced stage, and
systemic chemotherapy is often of limited benefit. METHODS Hybrid capture–based …
systemic chemotherapy is often of limited benefit. METHODS Hybrid capture–based …
Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets
Aim We queried whether extrahepatic cholangiocarcinoma featured clinically relevant
genomic alterations that could lead to targeted therapy. Methods Comprehensive genomic …
genomic alterations that could lead to targeted therapy. Methods Comprehensive genomic …